Third Harmonic Bio, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Third Harmonic Bio reveals plans to liquidate and dissolve the company, distributing remaining cash to stockholders, despite positive Phase 1 clinical trial results for THB335.
10-Q: Third Harmonic Bio Reports Increased R&D Spending in Q3 2024 as THB335 Clinical Trial Progresses
Third Harmonic Bio's Q3 2024 report reveals a significant increase in research and development expenses, primarily driven by the advancement of their lead drug candidate, THB335, into clinical trials.
10-Q: Third Harmonic Bio Reports Second Quarter 2024 Financial Results, Advances THB335 Clinical Program
Third Harmonic Bio's second quarter 2024 results show increased R&D spending as the company advances its lead drug candidate, THB335, into clinical trials.
Third Harmonic Bio announced its first quarter 2024 financial results, highlighting progress in its clinical development program for THB335 and key leadership appointments.